$NKTR News

Why I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension Data

Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $80

Nektar Therapeutics To Offer Up To $150M In Common Stock Via Equity Distribution Agreement

Piper Sandler Maintains Overweight on Nektar Therapeutics, Raises Price Target to $192

Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript

NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q1 Earnings Beat Revenue Estimates but EPS Miss Drags Stock Lower

Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate

Nektar Therapeutics: This Stock Went Up 10x In The Last Year And It's Still Cheap

Citigroup Maintains Buy on Nektar Therapeutics, Raises Price Target to $151

Wedbush Maintains Neutral on Nektar Therapeutics, Raises Price Target to $95

Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development

Nektar Therapeutics Launches $250M Common Stock Offering

Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata - Slideshow

Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript

HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $185

BTIG Maintains Buy on Nektar Therapeutics, Raises Price Target to $178

Why Are Nektar Shares Up Monday?

Nektar Therapeutics shares are trading higher after the company announced results from a blinded 16-week treatment extension period in its Phase 2b REZOLVE-AA study.

Nektar Therapeutics shares are trading higher after the company announced results from a blinded 16-week treatment extension period in its Phase 2b REZOLVE-AA study.

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times